RENSSELAER POLYTECHNIC INSTITUTE v. SAMSUNG ELECTRONICS AMERICA, INC.

CourtDistrict Court, D. New Jersey
DecidedSeptember 6, 2022
Docket2:19-cv-20097
StatusUnknown

This text of RENSSELAER POLYTECHNIC INSTITUTE v. SAMSUNG ELECTRONICS AMERICA, INC. (RENSSELAER POLYTECHNIC INSTITUTE v. SAMSUNG ELECTRONICS AMERICA, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
RENSSELAER POLYTECHNIC INSTITUTE v. SAMSUNG ELECTRONICS AMERICA, INC., (D.N.J. 2022).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

RENSSELAER POLYTECHNIC INSTITUTE, Plaintiff, Civ. No. 19-20097 (KM) (ESK) v. OPINION & ORDER SAMSUNG ELECTRONICS AMERICA, (Markman Claim Construction) INC. and SAMSUNG ELECTRONICS CO., LTD.,

Defendants.

KEVIN MCNULTY, U.S.D.J.: This Opinion contains the Court’s construction of key patent terms following a Markman hearing.1 This patent infringement case is brought by Rensselaer Polytechnic Institute (RPI) against defendants Samsung Electronics America, Inc., and Samsung Electronics Co., Ltd. (collectively, “Samsung”). The patents-in-suit are Patent Nos. 6,906,339 (“the ’339 Patent”) and 7,253,119 (“the ’119 Patent”). These patents describe a method for manufacturing semiconductor nanoparticles, also known as “quantum dots,” used in optical and electronic applications, including television displays. In approximately 2015, Samsung began manufacturing television sets with “quantum dots” which are alleged by RPI to violate the asserted patents. Accordingly, RPI brought this infringement suit against Samsung in November 2019. I held a Markman hearing in October 2021. I. BACKGROUND The two patents at issue—the ‘339 patent and the ‘119 patent—concern a method of synthesizing semiconductor nanoparticles (or “quantum dots”) for use in optical and electronic applications. (DE 1 ¶¶ 8-11; ’399 Patent 1:15–20;

1 The reference is to Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). ‘119 Patent Abstract, 1:18-23.)2 The patented method of synthesizing these particles uses “elemental passivation,” a process that can prevent or discourage such nanoparticles from “agglomerating,” that is, sticking together. (‘339 Patent Abstract, 3:25-39, 3:60-63; ‘119 Patent 3:30-44, 3:45-65.) This method was intended to be an improvement over the existing method of synthesizing nanoparticles with “shells,” a structure referred to as “core-shell architecture,” because such shelled nanoparticles were difficult to manufacture and performed poorly. (‘339 Patent 1:21-58, 3:40-57; ‘119 Patent 1:24-60.) Instead, the patented process of “elemental passivation” involves the binding of chemical elements (called “dangling bonds”) to parts of the nanoparticle’s surface to prevent agglomeration. (‘339 Patent Abstract, 2:55-62, 3:25-39, 4:42-62; ‘119 Patent 3:30-44, 3:45-65.) The synthesis of these particles comprises two major steps: the first step, in which nanoparticles are formed in an aqueous solution, and the second in which a chemical agent “etches” the nanoparticles to a desired size. (‘339 Patent Abstract, 2:49-54, 3:64-4:10, 20:16-31; ‘119 Patent 2:54-59.) Information gleaned from photon correlated spectroscopy (“PCS”) is used to determine that the nanoparticles are of the

2 Certain citations to the record are abbreviated as follows: DE = docket entry RPI Opening Br. = RPI’s Opening Claim Construction Brief (DE 95) Samsung Opening Br. = Samsung’s Opening Claim Construction Brief (DE 94) RPI Resp. Br. = RPI’s Response Brief (DE 99) Samsung Resp. Br. = Teva’s Response Brief (DE 100) ’339 Patent = Patent No. 6,906,339 (DE 1-1) ’119 Patent = Patent No. 7,253,119 (DE 1-2) Fahlman Decl. = Declaration of Bradley Fahlman, Ph.D. (DE 94-1) Green Decl. = Declaration of Mark Green, Ph.D. (DE 94-2) Reisberg Decl. = Declaration of Joshua S. Reisberg. (DE 94-3) Palomaki Decl. = Declaration of Peter K. B. Palomaki, Ph.D. (DE 95-1.) Hrg Tr. = Transcript of Markman hearing held on October 19, 2021 (DE 111) correct size and are not agglomerating. (‘339 Patent 2:43-48, 17:3-24, 20:63- 21:11; ‘119 Patent 1:61-2:53.) The ‘339 patent and the ‘119 patent were developed and invented by RPI’s Dr. Partha Dutta and were issued by the U.S. Patent Office in 2005 and 2007. (DE 1 ¶¶ 8-11.) At least as early as 2015, Samsung began manufacturing “QLED” televisions using “quantum dot” semiconductor nanoparticles, products that RPI alleges infringed these patents by employing elementally passivated nanoparticles to make the television display screens. (See DE 1 ¶¶ 12-34.) RPI filed suit against Samsung on November 19, 2021. (DE 1.) Following relevant discovery, the parties presented their dispute as to the meaning of certain claims. On October 19, 2021, I convened a Markman claim- construction hearing. (Hrg Tr.) What follows is my ruling as to the construction of the disputed claims. II. STANDARD A patent infringement case involves two steps. First, the court determines the meaning of claims in the patent. Amgen Inc. v. Amneal Pharms. LLC, 945 F.3d 1368, 1375 (Fed. Cir. 2020). Second, the court compares the claims, as construed, to the allegedly infringing product. Id. We are now concerned with the first step, known as claim construction. When, as here, the parties dispute the meaning of the patent’s claims, the court must resolve those disputes. Bayer Healthcare LLC v. Baxalta Inc., 989 F.3d 964, 977 (Fed. Cir. 2021). This task primarily requires construal of written documents (quintessentially, the patent itself), but some factual determinations may be needed to assist in understanding the written words. Teva Pharms. USA, Inc. v. Sandoz, Inc., 574 U.S. 318, 325–26 (2015). Accordingly, there is a hierarchy of sources to be considered when construing a claim, arranged in decreasing order of importance. Profectus Tech. LLC v. Huawei Techs. Co., 823 F.3d 1375, 1381 (Fed. Cir. 2016). Of course, I “begin with the words of the claims themselves.” Allergan Sales, LLC v. Sandoz, Inc., 935 F.3d 1370, 1373 (Fed. Cir. 2019) (citation omitted). Those words receive the meaning “a person of ordinary skill in the art” (“POSA”) would give them. Id. (citation omitted). A POSA would interpret those words in the context of the rest of the patent document, including the specification which describes the invention. Id. at 1373 & n.6. The prosecution history, i.e., proceedings before the U.S. Patent and Trademark Office that led to approval of the patent, can further illuminate a term. Id. at 1373 & n.7. The foregoing items constitutes “intrinsic evidence,” i.e., evidence from within the patent process itself. I may also turn to “extrinsic evidence,” or evidence outside the patent and prosecution history. Id. at 1373 & n.8. Such extrinsic evidence includes “expert and inventor testimony, dictionaries, and learned treatises.” Phillips v. AWH Corp., 415 F.3d 1303, 1317 (Fed. Cir. 2005) (en banc). Such extrinsic evidence is second-priority; it cannot “trump the persuasive intrinsic evidence.” Immunex Corp. v. Sanofi-Aventis U.S. LLC, 977 F.3d 1212, 1221–22 (Fed. Cir. 2020) (citation omitted). III. DISCUSSION The parties have identified nine claim terms whose meaning are in dispute. I discuss them in sections III.A–C.

A. Structure and Characterization Terms “nanoparticle” Term RPI’s Construction Samsung’s Construction

“nanoparticle” a nanoscale particle a nanoscale particle that does not have any shells (All asserted claims.)

Foundational to both the asserted patents and the dispute before me is the term “nanoparticle,” a word that the parties agree refers to a “nanoscale particle,” i.e., a particle with an approximate diameter between 2 and 100 nanometers. Their disagreements arise over whether the term includes nanoparticles with “shells” or only those without shells. (RPI Opening Br. at 12; Samsung Opening Br.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ecolab, Inc. v. FMC Corp.
569 F.3d 1335 (Federal Circuit, 2009)
Grober v. Mako Products, Inc.
686 F.3d 1335 (Federal Circuit, 2012)
Allergan Sales, LLC v. Sandoz, Inc.
935 F.3d 1370 (Federal Circuit, 2019)
Bayer Healthcare LLC v. Baxalta Inc.
989 F.3d 964 (Federal Circuit, 2021)

Cite This Page — Counsel Stack

Bluebook (online)
RENSSELAER POLYTECHNIC INSTITUTE v. SAMSUNG ELECTRONICS AMERICA, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/rensselaer-polytechnic-institute-v-samsung-electronics-america-inc-njd-2022.